Unknown

Dataset Information

0

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.


ABSTRACT: BACKGROUND:Sofosbuvir is a chain-terminating nucleotide analogue inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase that is efficacious in subjects with HCV genotype 1-6 infection. Sofosbuvir resistance is primarily conferred by the S282T substitution in NS5B. METHODS:NS5B sequencing and susceptibility testing of HCV from subjects infected with genotypes 1-6 who participated in phase 2 and 3 sofosbuvir clinical trials was performed. RESULTS:No NS5B variants present at baseline among 1645 sofosbuvir-treated subjects were associated with treatment failure; sofosbuvir susceptibility was within 2-fold of reference. Among 282 subjects who did not achieve sustained virologic response, no novel sofosbuvir resistance-associated variants were identified, and the NS5B changes observed did not confer significant reductions in sofosbuvir susceptibility. In 1 subject with S282T observed at relapse 4 weeks after sofosbuvir monotherapy, the resistant variant (13.5-fold reduced sofosbuvir susceptibility, replication capacity <2% of control) became undetectable by deep sequencing 12 weeks after treatment. L159F and V321A were identified as treatment-emergent variants but did not confer resistance to sofosbuvir in the replicon system. CONCLUSIONS:These data demonstrate a uniform susceptibility of subject-derived HCV to sofosbuvir, and also show that selection of sofosbuvir-resistant HCV is exceedingly rare and is associated with a significant reduction in viral fitness.

SUBMITTER: Svarovskaia ES 

PROVIDER: S-EPMC6433438 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC6281391 | BioStudies
2016-01-01 | S-EPMC4808174 | BioStudies
2014-01-01 | S-EPMC4139363 | BioStudies
2013-01-01 | S-EPMC3878512 | BioStudies
2020-01-01 | S-EPMC7038289 | BioStudies
2014-01-01 | S-EPMC4586065 | BioStudies
2008-01-01 | S-EPMC2592884 | BioStudies
2011-01-01 | S-EPMC3135787 | BioStudies
2011-01-01 | S-EPMC3209386 | BioStudies
2014-01-01 | S-EPMC3993261 | BioStudies